期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 65, 期 1, 页码 8-20出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2007.09.006
关键词
colorectal cancer; cetuximab (Erbitux (TM)); panitumumab (Vectibix (TM)); gefitinib; erlotinib (Tarceva (TM)); EGFR inhibition; clinical trial
资金
- NATIONAL CANCER INSTITUTE [T32CA009172] Funding Source: NIH RePORTER
- NCI NIH HHS [T32 CA009172] Funding Source: Medline
Although significant advances have been made in the treatment of metastatic colorectal cancer (CRC), prognosis remains poor, with a 5-year survival of less than 10%. Monoclonal antibodies that target the epidermal growth factor receptor (EGFR) have shown clinical benefit as single agents and in combination with standard chemotherapy in the refractory setting, with tolerable toxicity. This article will discuss the role of the EGFR pathway in the pathogenesis of CRC, the data supporting the current use of cetuximab and panitumumab in the treatment of CRC, and clinical trials of EGFR tyrosine kinase inhibitors in CRC. Novel strategies of targeting the EGFR pathway to improve efficacy, as well as ongoing research in identifying molecular predictors of response to anti-EGFR agents, will also be reviewed. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据